Pay in 4 interest-free payments of $7.41 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Tirzepatide is a dual agonist of GIP and GLP-1 receptors, acting in an integrated way across incretin pathways
The research identified nearly 200 locations selling compounded GLP-1s in Colorado
The averages in clinical trials run by the drugs manufacturer were: Wegovy (injection): 15% weight loss in 68 weeks Wegovy (pill): 14% weight loss in 64 weeks Ozempic: 7% weight loss in 30 weeks Rybelsus: 4% weight loss in 6 months These statistics are from clinical trials, where the research team controls many of the variables
Summary: GLP-1 receptor agonists do not directly cause irregular periods, but the significant weight loss they produce can temporarily affect menstrual regularity through metabolic and hormonal changes
Safety Profile Retatrutide emerges as a therapeutic option for subcutaneous fat loss, particularly in individuals with overweight or obesity or type 2 diabetes
Until retatrutide receives a positive marketing authorisation from the MHRA, it cannot be legally sold, supplied, or prescribed as a standard treatment in the UK
